What is the appropriate dosing regimen for a 500 mg capecitabine tablet in a patient with breast cancer?

Capecitabine Dosing for Breast Cancer

For breast cancer, capecitabine 500 mg tablets should be dosed at 1000-1250 mg/m² orally twice daily for 14 days, followed by a 7-day rest period, repeated every 21 days. 1

Standard Dosing Regimens

Monotherapy

• Standard dose: 1000-1250 mg/m² PO twice daily, days 1-14, cycled every 21 days 1
• North American consideration: The 1000 mg/m² twice daily starting dose is recommended for good performance status patients, with close monitoring in the first cycle for toxicity 2
• North American patients experience greater toxicity with capecitabine than European patients, where 1250 mg/m² is standard 2

Combination Regimens

Docetaxel + Capecitabine:

• Docetaxel 75 mg/m² IV day 1
• Capecitabine 950 mg/m² PO twice daily, days 1-14
• Cycled every 21 days 1

Ixabepilone + Capecitabine (Category 2B):

• Ixabepilone 40 mg/m² IV day 1
• Capecitabine 2000 mg/m² PO days 1-14
• Cycled every 21 days 1

Lapatinib + Capecitabine (HER2-positive, trastuzumab-exposed):

• Lapatinib 1250 mg PO daily, days 1-21
• Capecitabine 1000 mg/m² PO twice daily, days 1-14
• Cycled every 21 days 1

Trastuzumab + Capecitabine (HER2-positive):

• Capecitabine 1000-1250 mg/m² PO twice daily, days 1-14
• Cycled every 21 days
• Plus standard trastuzumab dosing 1

Adjuvant Setting for Triple-Negative Breast Cancer

For patients with residual disease after neoadjuvant chemotherapy, offer 6-8 cycles of adjuvant capecitabine at 1250 mg/m² twice daily for 14 days, repeated every 21 days. 3

Key Considerations:

• Preferentially indicated for hormone receptor-negative, HER2-negative (triple-negative) breast cancer with pathologic residual disease after standard anthracycline-taxane neoadjuvant therapy 3
• The 1250 mg/m² dose is associated with higher toxicity in patients ≥65 years old 3
• Recent real-world data shows median relative dose intensity of only 60% in US populations, significantly lower than the 78.7% in CREATE-X trial 4
• Improved recurrence-free survival (HR 0.70), distant recurrence-free survival (HR 0.71), and overall survival (HR 0.66) demonstrated 5

Critical Dose Modifications

Renal Impairment

• Moderate impairment (CrCl 30-50 mL/min): Reduce starting dose to 850 mg/m² twice daily 6
• Severe impairment (CrCl <30 mL/min): Contraindicated - systemic exposure to toxic metabolite FBAL increases by 258% 6

Hepatic Impairment

• Mild to moderate dysfunction: Exercise caution; AUC and Cmax of capecitabine increase by 60% 6
• Severe dysfunction: Effect unknown; use with extreme caution 6

Age-Related Adjustments

• Patients ≥65 years: Consider starting at lower end of dosing range (1000 mg/m² vs 1250 mg/m²) due to 15% increase in FBAL exposure with age 6

Administration Guidelines

Take with water within 30 minutes after a meal - food reduces Cmax by 60% and AUC by 35%, which is the intended pharmacokinetic profile 6

Calculating Total Daily Dose from 500 mg Tablets:

For a patient with BSA of 1.8 m²:

• 1000 mg/m² dose: 1.8 × 1000 = 1800 mg twice daily = four 500 mg tablets twice daily
• 1250 mg/m² dose: 1.8 × 1250 = 2250 mg twice daily = five 500 mg tablets twice daily (round to nearest 500 mg)

Common Toxicities and Management

Hand-foot syndrome is the most frequent adverse event (73% all grades, 11% grade 3) 3, 4

• Requires dose reduction or interruption
• Prophylactic measures should be implemented

Other significant toxicities:

• Diarrhea (27%) 4
• Neutropenia (19% grade 3/4 in combination regimens) 7
• Fatigue (22%) 4

Warfarin Interaction Warning

Capecitabine increases warfarin AUC by 57% and INR by 2.8-fold - close INR monitoring is mandatory 6

Evidence Quality Note

The dosing recommendations are based on NCCN Guidelines (2011) 1 and FDA labeling 6, with recent ASCO guidelines (2018) 3 supporting adjuvant use in triple-negative breast cancer. Real-world data consistently shows North American patients require lower doses than the European standard of 1250 mg/m² 2, 4.